Lawsuits regarding Actos have started going to trial alleging the diabetes drug causes bladder cancer and that Takeda Pharmaceuticals was aware. We have blogged before about Actos and after a jury in Louisiana awarded over 9 billion dollars in punitive damages it is time to blog about this issue again.
As a reminder many people who previously took the drug Actos for their diabetes were diagnosed with Bladder Cancer.
On June 15, 2011 the U.S. Food and Drug Administration (FDA) announced that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.
Actos is manufactured by Takeda Pharmaceuticals and was first approved for Diabetes Type II in 1999. Actos was sold in combination with metformin (Actoplus Met, Actoplus Met XR) and glimepiride (Duetact).
The FDA announced in 2010 that although Takeda Pharmaceuticals had conducted their own planned data review which indicated no statistically significant association between Actos and bladder cancer, the FDA’s own analysis of that data indicated that a correlation between the length of time patients were taking Actos and the development of bladder cancer was significant. In August 2011, the FDA required updated drug labels for Actos which included that use of this drug for over one year may be associated with an increased risk of bladder cancer.
The FDA is also aware of a recent epidemiological study conducted in France which suggests an increased risk of bladder cancer with pioglitazone. Based on the results of this study, France has suspended the use of pioglitazone and Germany has recommended not to start pioglitazone in new patients.
Our firm has filed suit on behalf of clients who have developed bladder cancer after taking this drug. We are reviewing additional cases for filing suit. At this time Actos cases are in litigation and have not been settled so there is no current settlement.
If you have taken Actos or any pioglitazone derivative medication for over a year and have developed bladder cancer our firm is reviewing these cases.
Please contact our office for a free review.